Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK inhibition with tofacitinib for remission induction in early psoriatic arthritis
2019-004177-35Phase 4Active
- Sponsor
- UZ Leuven
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of tofacitinib in psoriatic arthritis (PsA), sponsored by UZ Leuven. Primary endpoint: Clinical remission at week 24. Started Dec 2019; status: active.
02
Drugs
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2019-004177-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004177-35.